JOHN H. WALSH, M.D.; RONALD K. TOMPKINS, M.D.; IAN L. TAYLOR, Ph.D.; JUAN LECHAGO, M.D., Ph.D.; JACK HANSKY, M.D.
With the advent of radioimmunoassay and immunocytochemical methods, the peptides of the gastrointestinal tract have been identified and measured. Gastrinoma and insulinoma syndromes have been well characterized. The pancreatic cholera syndrome and some of the evidence that the major manifestations of this disease may be mediated by vasoactive intestinal peptide have been re-examined. Pancreatic polypeptide seems to be an ideal peptide for study of vagal-cholinergic mechanisms that regulate hormone release; it also appears to be a tumor marker for several types of pancreatic endocrine tumors, particularly those of pancreatic cholera. Secretin and cholecystokinin are important regulators of pancreatic exocrine secretion and have been used to test pancreatic function, but there is little evidence that they account for clinical disease. Glucagon-secreting tumors produce a clinical syndrome of diabetes mellitus and distinctive skin lesions, which can be cured by tumor resection. Hormone-secreting tumors may provide insight into normal gut physiology.
WALSH JH, TOMPKINS RK, TAYLOR IL, LECHAGO J, HANSKY J. Gastrointestinal Hormones in Clinical Disease: Recent Developments. Ann Intern Med. ;90:817–828. doi: 10.7326/0003-4819-90-5-817
Download citation file:
Published: Ann Intern Med. 1979;90(5):817-828.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use